How plan sponsors can use biosimilars to support employee health, reduce drug costs
Despite the safety and efficacy of biosimilars — and the potential cost savings they offer — uptake among private payers has been low historically and is only starting to gain steam, said Neda Nasseri, pharmacist and private payer product director at Desjardins Insurance, during Benefits Canada’s 2023 Face to Face Drug Plan Management Forum in December. The insurer first developed […]
- January 22, 2024 January 22, 2024
- 07:54